Is protracted low-dose temozolomide feasible in glioma patients?

Department of Medical Oncology, University Hospital of Padova, Padova, Italy.

Abstract
The authors investigated the safety of 75 mg/m² temozolomide for 21 days every 28 days in glioma patients. This schedule could lead to DNA repair enzyme O6-alkylguanine-DNA alkyltransferase depletion, contributing to overcoming drug resistance. Although Phase III studies are forthcoming, no data are available on the long-term toxicity of temozolomide, which, in this series, incurred prolonged, cumulative lymphopenia, which leads to a high incidence of infections.

Comment in

PMID: 16476947 [PubMed - indexed for MEDLINE]

MeSH Terms, Substances

LinkOut - more resources